As part of our mission to bring you trustworthy information that’s easy to understand, our editorial team hosts weekly LiveTalks with experts, advocates and…
Game of Thrones star Emilia Clarke is missing ‘quite a bit’ of her brain. How can people survive and thrive after brain injury? In a…
Lecanemab, Eisai and Biogen’s experimental anti-amyloid Alzheimer’s drug, which recently wrapped its Phase 3 clinical trials, continues to make the news. Some of these…
The prevalence of dementia is rising globally — and efforts to fight the stigma around dementia are on the rise, too. In the Netherlands, elementary…
A few months before Jasja De Smedt Kotterman’s mother died of Alzheimer’s at age 76, Kotterman found her mother staring vacantly at a meal,…
The United States imposed a blockade against Cuba in 1961, and currently there isn’t much collaboration — or even, much communication — about medical…
The majority of experimental Alzheimer’s drugs are being designed to halt the progression of the disease — a strategy which so far has yielded…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…
Could insulin treat Alzheimer’s the same way it treats diabetes? Evidence shows Alzheimer’s might be more similar to a metabolic disorder, like diabetes, than…
When people log in to join a Jewish Family & Children’s Service memory cafe online, they might hear from an Afro-Latin music expert about…
New data presented at CTAD about an existing agitation drug, brexpiprazole, in trials for patients with Alzheimer’s, bears potential good news when it comes…
About 90 percent of people with Alzheimer’s disease show behavioral symptoms like agitation, irritability, and anger during the course of the disease. If a caregiver…
This article is part of the series Diversity & Dementia, produced by Being Patient with support provided by Eisai. After Kunle Adewale’s stepmother had a stroke,…
Hello from the CTAD Alzheimer’s research conference in San Francisco, where I am attending this year’s meeting on the latest announcements on Alzheimer’s disease…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD in 2022, showing the drug is as safe as the placebo…